Identifiant pérenne de la notice : 212499971
Notice de type
Notice de regroupement
Note publique d'information : An estimated 1.5 million patients in the United States are diagnosed with cancer every
year and over half-a-million individuals die of the disease. Since the vast majority
of the deaths occur after medical intervention with anticancer therapy, both conventional
chemotherapy and novel targeted therapy, it can be concluded that these patients die
from drug resistant cancers. A growing number of studies have revealed that mechanisms
underlying the development of drug resistance in cancer cells are manifold and complex
and very likely are dependent on cell and microenvironment context. In view of these
facts, it is important to document the mechanisms of drug resistance and understand
which are the dominant resistance pathways in a particular tumor type that could provide
potential therapeutic targets in a clinical setting. This book serves as a single
source for the current knowledge on genetic and epigenetic alterations that contribute
to the development of drug resistance. Comprehensive reviews written by renowned experts
provide great insight on the current knowledge on drug resistance mechanisms. This
book is a ready source of information to clinicians, cell and cancer biologists and
defines molecular drug resistance mechanisms that are challenging scientists and clinical
oncologists today. About Editors: Dr. Kapil Mehta is a Professor in the Department
of Experimental Therapeutics, The University of Texas M. D Anderson Cancer Center,
Houston, TX. He has published widely and received several patents on novel discoveries
relating to drug resistance in the field of cancer therapeutics. Dr. Zahid H. Siddik
is also a Professor in the Department of Experimental Therapeutics at The University
of Texas M.D. Anderson Cancer Center. He has studied extensively the mechanisms of
drug action and resistance, and is recognized for his seminal studies with platinum-based
antitumor agents